韩国输血依赖性铁过载除铁治疗指南 2013.pdf

SPECIAL ARTICLE Oncology Hematology /10.3346/jkms.20563 • J Korean Med Sci 2013; 28: 1563-1572 Korean Guideline for Iron Chelation Therapy in Transfusion- Induced Iron Overload 1 2 Jun Ho Jang, Je-Hwan Lee, Many Korean patients with transfusion-induced iron overload experience serious clinical 3 4 Sung-Soo Yoon, Deog-Yeon Jo, sequelae, including organ damage, and require lifelong chelation therapy. However, due 5 6 Hyeoung-Joon Kim, Jooseop Chung, to a lack of compliance and/or unavailability of an appropriate chelator, most patients and Jong Wook Lee7 have not been treated effectively. Deferasirox (DFX), a once-daily oral iron chelator for both adult and pediatric patients with transfusion-induced iron overload, is now available 1Division of Hematology-Oncology, Department of in Korea. The effectiveness of deferasirox in reducing or maintaining body iron has been Medicine, Samsung Medical Center, Sungkyunkwan 2 demonstrated in many studies of patients with a variety of transfusion-induced anemias University School of Medicine, Seoul; Department of Hematology, Asan Medical Center, University of such as myelodysplastic syndromes, aplastic anemia, and other chronic anemias. The 3 Ulsan College of Medicine, Seoul; Division of recommended initial daily dose of DFX is 20 mg/kg body weight, taken on an empty Hematology-Oncology, Seoul National University stomach at least 30 min before food and serum ferritin levels should be maintained below College of Medicine, Seoul; 4Division of Hematology-Oncology, Chungnam